164 related articles for article (PubMed ID: 19605505)
1. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group.
Sperr WR; Wimazal F; Kundi M; Baumgartner C; Nösslinger T; Makrai A; Stauder R; Krieger O; Pfeilstöcker M; Valent P
Ann Oncol; 2010 Jan; 21(1):114-9. PubMed ID: 19605505
[TBL] [Abstract][Full Text] [Related]
2. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation.
Boehm A; Sperr WR; Leitner G; Worel N; Oehler L; Jaeger E; Mitterbauer M; Haas OA; Valent P; Kalhs P; Rabitsch W
Eur J Clin Invest; 2008 Dec; 38(12):945-52. PubMed ID: 19021720
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
4. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.
Breccia M; Frustaci AM; Cannella L; Stefanizzi C; Latagliata R; Cartoni C; Diverio D; Guarini A; Nanni M; Rago A; Cimino G; Alimena G
Hematol Oncol; 2009 Sep; 27(3):148-53. PubMed ID: 19274612
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.
Lee JH; Lee JH; Lim SN; Kim DY; Kim SH; Lee YS; Kang YA; Kang SI; Jeon MJ; Seol M; Seo EJ; Chi HS; Park CJ; Jang S; Yun SC; Lee KH
Bone Marrow Transplant; 2010 Mar; 45(3):450-7. PubMed ID: 19668236
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
7. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.
Balleari E; Salvetti C; Del Corso L; Filiberti R; Bacigalupo A; Bellodi A; Beltrami G; Bergamaschi M; Berisso G; Calzamiglia T; Carella AM; Cavalleri M; Da Col A; Favorini S; Forni GL; Goretti R; Miglino M; Mitscheuning L; Molinari E; Racchi O; Scudeletti M; Tassara R; Gobbi M; Lemoli R; Clavio M
Leuk Res; 2015 Aug; 39(8):846-52. PubMed ID: 26145790
[TBL] [Abstract][Full Text] [Related]
8. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune diseases and myelodysplastic syndromes.
Komrokji RS; Kulasekararaj A; Al Ali NH; Kordasti S; Bart-Smith E; Craig BM; Padron E; Zhang L; Lancet JE; Pinilla-Ibarz J; List AF; Mufti GJ; Epling-Burnette PK
Am J Hematol; 2016 May; 91(5):E280-3. PubMed ID: 26875020
[TBL] [Abstract][Full Text] [Related]
10. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV
Eur J Haematol; 2018 Feb; 100(2):198-205. PubMed ID: 29168234
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
[TBL] [Abstract][Full Text] [Related]
12. Combination of Frailty Status and Comorbidity Score Improves the Stratification of Survival in Patients With Myelodysplastic Syndrome Owing to Good Predictive Capability for Infection-related Mortality.
Sakatoku K; Takeoka Y; Miura A; Araki T; Fujitani Y; Yamamura R; Nakamae H; Ohta K; Hino M
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):799-805. PubMed ID: 31648956
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.
Breccia M; Federico V; Latagliata R; Mercanti C; D'Elia GM; Cannella L; Loglisci G; Salaroli A; Santopietro M; Alimena G
Leuk Res; 2011 Feb; 35(2):159-62. PubMed ID: 20594593
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH
BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830
[TBL] [Abstract][Full Text] [Related]
15. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
16. Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.
Yamasaki S; Suzuki R; Hatano K; Fukushima K; Iida H; Morishima S; Suehiro Y; Fukuda T; Uchida N; Uchiyama H; Ikeda H; Yokota A; Tsukasaki K; Yamaguchi H; Kuroda J; Nakamae H; Adachi Y; Matsuoka KI; Nakamura Y; Atsuta Y; Suzumiya J
Bone Marrow Transplant; 2017 Jul; 52(7):969-976. PubMed ID: 28368379
[TBL] [Abstract][Full Text] [Related]
17. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation.
Alam N; Atenafu EG; Kuruvilla J; Uhm J; Lipton JH; Messner HA; Kim DH; Seftel M; Gupta V
Bone Marrow Transplant; 2015 Sep; 50(9):1180-6. PubMed ID: 26121109
[TBL] [Abstract][Full Text] [Related]
19. Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusting for comorbidities.
Sevindik OG; Guc Z; Kahraman S; Medeni Solmaz S; Katgi A; Acar C; Alacacioglu I; Piskin O; Ozsan GH; Demirkan F; Undar B; Ozcan MA
Leuk Lymphoma; 2015; 56(9):2552-5. PubMed ID: 25669924
[TBL] [Abstract][Full Text] [Related]
20. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
Lim ZY; Ingram W; Brand R; Ho A; Kenyon M; Devereux S; Marsh J; Mufti GJ; Pagliuca A
Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
